|
|
Strategic Alliances in the Global IVD MarketsPublished by: Frost & Sullivan Published: Aug. 23, 2007 - 80 Pages Table of Contents
AbstractThis Frost & Sullivan research service titled Strategic Alliances in the Global IVD Market provides an overview of the strategic alliances taking place in this market and offers strategic solutions to manufacturers to gain advantage in this growing market.This analysis is available through our Drug Discovery Technologies Growth Partnership Service programme. With this programme, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: The following technologies are covered in this research: Recent Alliances between Healthcare Imaging and Diagnostics Companies Reveal Mutual Goal of Reducing Costs and Improving Healthcare Efficiency From being primarily driven by bench top instruments with innovative assays, the global in vitro diagnostics (IVD) market has continuously evolved over the last decade and is now more focused on larger systems that are integrated with different software and automation components and on developing screening and disease confirmation tests. The scene is set for more change as evidenced by the growing number of acquisitions taking place. For instance, Siemens Medical Solutions, a leader in diagnostics imaging, recently acquired two IVD manufacturers, Diagnostic Products Corp. (DPC) and Bayer Diagnostics and forged a strong place for itself in the IVD market. Siemens’ long-term strategy has been to improve healthcare efficiency by providing products across the entire spectrum and its realisation that IVD was missing from this continuum of prevention and early detection, diagnosis, therapy and care prompted it to make these strategic acquisitions. Today, Siemens holds the unique position of being the first company to bring IVD, in vivo diagnostics and healthcare IT under one roof, but faces constant competitive threats from other companies looking to enter the market. However, Frost & Sullivan believes that the IVD market holds enough potential to continue attracting such companies to participate and invest either through partnerships or acquisitions. Opportunities to enhance diagnostic management are ample and such alliances and collaborations are beneficial to both companies and patients. Recent acquisitions have also set off a new trend to combine early diagnosis with information technology to create a new ‘early health’ model of care focused on swift diagnosis, pre-symptomatic disease detection and prevention. "Manufacturers wishing to be a part of this novel model integrating pharmaceuticals or healthcare IT with the diagnostics industry need to anticipate opportunities before the competition and develop successful strategies and alliances resulting in advantages," says the analyst of this research service. "Research has shown that to succeed, companies must properly anticipate customer needs and competing technologies and have a mutual goal in reducing costs and improving healthcare efficiency." New Technologies Enable Growing Synergies between Diagnostics and Therapeutics There are several changes taking place in healthcare provision that are influencing the market for diagnostic products and the dynamics of the industry as a whole. IVD companies’ ability to anticipate and react in a timely manner to these changes will, to a great extent, determine the success or failure of new technologies. The fact that patients are taking greater responsibility for their healthcare decisions and have wider access to information on new technologies, thanks to the Internet, has empowered consumers who are playing a key role in driving demand. Healthcare demand is also fuelled by a rapidly ageing population and the availability of new and advanced technologies. Combined, these factors are placing considerable pressure on healthcare budgets. Faced with rising healthcare costs, private and public payers will require compelling evidence in the form of cost-benefit analyses to support the reimbursement of diagnostic and therapeutic products. "In this regard, the development of technologies that enable pre-symptomatic screening and individual patient risk profiles are likely to make a difference by establishing closer links between diagnostics and therapeutics," remarks the analyst. "The resulting ‘theranostics’ will bring more value to diagnostic tests, which are undervalued by healthcare payers and providers." As research evolves, so will the demand for more sophisticated detection technologies - for example, tests that specify the type of infection rather than merely detecting if a patient has influenza or pneumonia. Novel technologies are enabling panels to be developed to test for a range of infectious agents using a single sample. Researchers are establishing biomarkers that could offer significant predictive value and allow them to be used instead of invasive biopsies. Faced with demands for multiplexing, rapid turn-around time, sensitivity and specificity, while still remaining cost-effective, the challenge for IVD manufacturers will be to strike a balance between the various components of diagnostics systems: chemistry (which delivers the signal), detection instrumentation technology (hardware) and software. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||